The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
Open accessAbstract
BACKGROUND: CD22 expression occurs in >90% of patients with acute lymphocytic leukemia (ALL). Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, is active in ALL. METHODS: Patients with refractory‐relapsed ALL received treatment with inotuzumab. The first 49 patients received single‐dose, intravenous inotuzumab at doses of 1.3 to 1.8 mg/m2 every 3 to 4 weeks. In the next 41 patients, the schedule was modified to inotuzumab weekly at a dose of 0.8 mg/m2 on day 1 and at a dose of 0.5 mg/m2 on days 8 and 15, every 3 to 4 weeks, based on higher in vitro efficacy with more frequent exposure. RESULTS: Ninety patients were treated; 68% were in salvage 2 or beyond. Overall, 17 patients (19%) achieved a complete response (CR), 27 (30%) had a CR with no platelet recovery (CRp), and 8 (9%) had a bone marrow CR (no recovery of counts), for an overall response rate of 58%. Response rates were similar for single‐dose and weekly dose inotuzumab (57% vs 59%, respectively). The median survival was 6.2 months overall, 5.0 months with the single‐dose schedule, and 7.3 months with the weekly dose schedule. The median survival was 9.2 months for patients in salvage 1 (37% at 1 year), 4.3 months for patients in salvage 2, and 6.6 months for patients in salvage 3 or later. The median remission duration was 7 months. Reversible bilirubin elevation, fever, and hypotension were observed less frequently on the weekly dose. In total, 36 of 90 patients (40%) underwent allogeneic stem cell transplantation. Veno‐occlusive disease was noted in 6 of 36 patients after stem cell transplantation (17%), was less frequent after the weekly schedule (7%), and with less alkylators in the preparative regimen. CONCLUSIONS: Inotuzumab single‐agent therapy was highly active, safe, and convenient in patients with refractory‐relapsed ALL. A weekly dose schedule appeared to be equally effective and less toxic than a single‐dose schedule. Cancer 2013;119:2728–2736. © 2013 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 913
Thomas, D. A., Faderl, S., O'Brien, S., Bueso‐Ramos, C., Cortes, J., Garcia‐Manero, G., Giles, F. J., Verstovsek, S., Wierda, W. G., Pierce, S. A., et al. (2006) · Cancer · doi:10.1002/cncr.21776 · Cited by 566
Self-citationModern Therapy of Acute Lymphoblastic Leukemia
Bassan, R., & Hoelzer, D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1382 · Cited by 485
Thomas, D. A., O'Brien, S., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Wierda, W., Ravandi, F., Verstovsek, S., Jorgensen, J. L., Bueso-Ramos, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9456 · Cited by 416
Self-citationKantarjian, H., Thomas, D., Jorgensen, J., Jabbour, E., Kebriaei, P., Rytting, M., York, S., Ravandi, F., Kwari, M., Faderl, S., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70386-2 · Cited by 412
Self-citationAdult acute lymphoblastic leukemia: Concepts and strategies
Faderl, S., O'Brien, S., Pui, C., Stock, W., Wetzler, M., Hoelzer, D., & Kantarjian, H. M. (2010) · Cancer · doi:10.1002/cncr.24862 · Cited by 289
Self-citationRaetz, E. A., Cairo, M. S., Borowitz, M. J., Blaney, S. M., Krailo, M. D., Leil, T. A., Reid, J. M., Goldenberg, D. M., Wegener, W. A., Carroll, W. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3528 · Cited by 208
Thomas, D. A., Kantarjian, H., Smith, T. L., Koller, C., Cortes, J., O'Brien, S., Giles, F. J., Gajewski, J., Pierce, S., & Keating, M. J. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991001)86:7<1216::aid-cncr17>3.0.co;2-o · Cited by 196
Self-citationThorson, J., Sievers, E., Ahlert, J., Shepard, E., Whitwam, R., Onwueme, K., & Ruppen, M. (2000) · Current Pharmaceutical Design · doi:10.2174/1381612003398564 · Cited by 166
Outcome of adults with acute lymphocytic leukemia after second salvage therapy
O'Brien, S. M., Thomas, D. M., Ravandi, F., Faderl, S. H., Cortes, J. E., Borthakur, G., Pierce, S. A., Garcia‐Manero, G., & Kantarjian, H. M. (2008) · Cancer · doi:10.1002/cncr.23919 · Cited by 150
Self-citationRizzieri, D. A., Johnson, J. L., Byrd, J. C., Lozanski, G., Blum, K. A., Powell, B. L., Shea, T. C., Nattam, S. R., Hoke, E. E., Cheson, B. D., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12736 · Cited by 99
Management of Acute Lymphoblastic Leukemia in Older Patients
Larson, R. A. (2006) · Seminars in Hematology · doi:10.1053/j.seminhematol.2006.01.007 · Cited by 62
Cited by
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J.-M., Wei, A., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,143
Self-citationInotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O’Brien, S., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,413
Self-citationFry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., et al. (2018) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,335
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
Terwilliger, T., & Abdul-Hay, M. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.53 · Cited by 1,288
Topp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71170-2 · Cited by 1,269
Self-citation
Metadata
- Authors
- Kantarjian, H., Thomas, D., Jorgensen, J., Kebriaei, P., Jabbour, E., Rytting, M., York, S., Ravandi, F., Garris, R., Kwari, M., Faderl, S., Cortes, J., Champlin, R., & O'Brien, S.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2013-04-30
- Volume
- 119
- Issue
- 15
- Pages
- 2728-2736
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1488000644
- Cited by
- 306
- References
- 12
- FWCI
- 26.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.